HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the preclinical poster presentation titled, ...
Neoadjuvant TKI therapy in non-metastatic GIST patients can reduce surgical complexity, with CE-CT imaging predicting benefits in 22 of 39 patients. Significant tumor volume reduction was observed ...
Please provide your email address to receive an email when new articles are posted on . Platinum-doublet chemotherapy after initial response to EGFR TKI appeared associated with longer PFS but no OS ...
Study documents low use of immune checkpoint inhibitor-based combinations for first-line treatment of metastatic clear cell RCC and high attrition with subsequent therapy. Many patients with ...
Can adding a TKI that targets programmed death ligand 1 (PD-L1) to a monoclonal antibody that also targets PD-L1 improve outcomes over the monoclonal antibody alone in locally advanced, unresectable ...
Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite ...
In this segment on advanced renal cell carcinoma, Dr. McGregor explores the role of VEGFR TKI monotherapy in patients with favorable risk disease, where NCCN guidelines include both IO-TKI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results